Date:February 22, 2021	
Your Name:Qiang Li	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular	<u>signal-</u>
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): TLCR-21-147	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Dongmei Yu	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular sign	nal-
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): TLCR-21-147	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Zhengyuan Yu	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signa	al-
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): <u>TLCR-21-147</u>	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	☑None	
4	Consulting fees	☑None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Qian Gao	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular sig	<u>ınal-</u>
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): TLCR-21-147	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Ruifang Chen	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular	<u>signal-</u>
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): TLCR-21-147	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Lin Zhou	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular	signal-
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): TLCR-21-147	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021
Your Name:Rong Wang
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signa
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis
Manuscript number (if known): <u>TLCR-21-147</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Yan Li	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signa	1 <u> -</u>
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): <u>TLCR-21-147</u>	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Yulan Qian	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular sign	al-
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): TLCR-21-147	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021
Your Name:Jun Zhao
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signa
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis
Manuscript number (if known): <u>TLCR-21-147</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Rafael Rosell	_
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular s	signal-
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	-
Manuscript number (if known): TLCR-21-147	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	�ZNone	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Min Tao	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular sig	<u>gnal-</u>
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): <u>TLCR-21-147</u>	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus,	None	
manuscript writing or educational events		
Payment for expert testimony	VNone	
Support for attending meetings and/or travel	None	
Patents planned, issued or	None	
pending		
Participation on a Data Safety Monitoring Board or	None	
Advisory Board		
Leadership or fiduciary role	None	
committee or advocacy		
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical	2None	
writing, gifts or other services		
Other financial or non-	None	
financial interests		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Yufeng Xie	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular si	<u>gnal-</u>
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): TLCR-21-147	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	☑None	
4	Consulting fees	None	

5 Payment or honoraria for lectures, presentations,		None	
	manuscript writing or educational events		
6	Payment for expert testimony	vdNone	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	2None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	☑ None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
13	services Other financial or non-	- Nono	
13	financial interests	None	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:February 22, 2021	
Your Name:Chun Xu	
Manuscript Title: TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular sign	nal-
regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	
Manuscript number (if known): TLCR-21-147	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	☑None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	☑None	
4	Consulting fees	None	

5 Payment or honoraria for lectures, presentations,		None	
	manuscript writing or educational events		
6	Payment for expert testimony	vdNone	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	2None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	☑ None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
13	services Other financial or non-	- Nono	
13	financial interests	None	

None.

Please place an "X" next to the following statement to indicate your agreement: